Mariantonia Nacchio

Mariantonia Nacchio

Auto-generated profile, based on publicly available information

Mariantonia Nacchio

Department of Public Health, University of Naples Federico II, 80131 Naples, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2019 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
Claudio BellevicineClaudio Bellevicine
Claudio Bellevicine
IMIlaria Migliatico
Ilaria Migliatico
RSRoberta Sgariglia
Roberta Sgariglia
MNMariantonia Nacchio
Mariantonia Nacchio
EVElena Vigliar
Elena Vigliar
FNFor The Tiroide Network
For The Tiroide Network

1 July 2020 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
MNMariantonia Nacchio
Mariantonia Nacchio
RSRoberta Sgariglia
Roberta Sgariglia
VGValerio Gristina
Valerio Gristina
Pasquale PisapiaPasquale Pisapia
Pasquale Pisapia
FPFrancesco Pepe
Francesco Pepe
UMUmberto Malapelle
Umberto Malapelle
In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe® panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes included in the SiRe® panel, such as epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B (BRAF). Exon 2 p.G12C was the most common detected mutation (13/36, 36.1%). In conclusion, our data update and confirm that SiRe® NGS panel represents a robust analytical tool to assess KRAS mutational status on circulating tumor DNA. Further investigation is required to design more cost-effective diagnostic algorithms to harmonize clinical relevant biomarker testing on tissue and blood in advanced stage NSCLC clinical practice.

27 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
Pasquale PisapiaPasquale Pisapia
Pasquale Pisapia
FPFrancesco Pepe
Francesco Pepe
AIAntonino Iaccarino
Antonino Iaccarino
RSRoberta Sgariglia
Roberta Sgariglia
MNMariantonia Nacchio
Mariantonia Nacchio
Giancarlo TronconeGiancarlo Troncone
Giancarlo Troncone
Gain-of-function of V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) is one of the most frequent oncogenic mutations in numerous cancers, including thyroid papillary carcinoma, melanoma, colon, and lung carcinomas, and to a lesser extent, ovarian and glioblastoma multiforme. This mutation aberrantly activates the mitogen-activated protein (MAP) kinase extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, thereby eliciting metastatic processes. The relevance of BRAF mutations stems from its prognostic value and, equally important, from its relevant therapeutic utility as an actionable target for personalized treatment. Here, we discuss the double facets of BRAF. In particular, we argue the need to implement diagnostic molecular algorithms that are able to detect this biomarker in order to streamline and refine diagnostic and therapeutic decisions.

24 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
UMUmberto Malapelle
Umberto Malapelle
Paola ParentePaola Parente
Paola Parente
FPFrancesco Pepe
Francesco Pepe
CLCaterina De Luca
Caterina De Luca
Pasquale PisapiaPasquale Pisapia
Pasquale Pisapia
PGPaolo Graziano
Paolo Graziano
Immune-checkpoint inhibitors (ICIs) play a key role in the treatment of advanced stage colorectal cancer (CRC) patients featuring a deficient DNA mismatch repair (dMMR) system or a high microsatellite instability (MSI-H) profile. However, beyond the established role in CRC patients, ICIs have highly proven efficacy in other solid tumors featuring MSI-H/dMMR status represented by endometrial, gastric, ovarian, prostatic, and pancreatic carcinomas (EC, GC, OC, PrC, and PaC). Our aim was to compare the concordance rates among the Idylla™ MSI test, TapeStation 4200, and immunohistochemical (IHC) analysis in assessing MSI-H/dMMR status in EC, GC, OC, PrC, and PaC patients. The Sanger sequencing-based Titano MSI test was used in discordant cases. One hundred and eighty-five cases (n = 40 PrC, n = 39 GC, n = 38 OC, n = 35 PaC, and n = 33 EC) were retrospectively selected. MMR protein expression was evaluated by IHC. After DNA quality and quantity evaluations, the IdyllaTM and TapeStation 4200 platforms were adopted for the evaluation of MSI status. Remarkably, compared to IHC, the Idylla™ platform achieved a global concordance rate of 94.5% (154/163) for the microsatellite stable (MSS)/proficient MMR (pMMR) cases and 77.3% (17/22) for the MSI-H/dMMR cases. Similarly, a global concordance rate of 91.4% (149/163) and 68.2% (15/22) for MSS/pMMR and MSI-H/dMMR cases was also identified between IHC and the TapeStation 4200 microfluidic system. In addition, a global concordance of 93.1% (148/159) and 69.2% (18/26) for MSS/pMMR and MSI-H/dMMR cases was observed between the Idylla™ and TapeStation 4200 platforms. Discordant cases were analyzed using the Titano MSI kit. Overall, our data pinpointed a central role for molecular techniques in the diagnostic evaluation of dMMR/MSI-H status not only in CRC patients but also in other types of solid tumors.

2 October 2018 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
FPFrancesco Pepe
Francesco Pepe
CLCaterina De Luca
Caterina De Luca
RSRiccardo Smeraglio
Riccardo Smeraglio
Pasquale PisapiaPasquale Pisapia
Pasquale Pisapia
RSRoberta Sgariglia
Roberta Sgariglia
UMUmberto Malapelle
Umberto Malapelle
Aims: Following the development for liquid biopsies of the SiRe next-generation sequencing (NGS) panel that covers 568 clinical relevant mutations in EGFR, KRAS, NRAS, BRAF, cKIT and PDGFRa genes, in this current study, we apply this small NGS panel on tissue samples of lung cancer. Methods: A total of 322 specimens were prospectively tested. Technical parameters were analysed on both cytological and histological samples. In a subset of 75 samples, the EGFR SiRe results were compared with those generated by the European Community (CE)–IVD EGFR assay on Idylla platform. Clinical outcomes of 11 patients treated, on the basis of SiRe results, were also evaluated. Results: Only 28 (8.7%) specimens failed to produce a library; out of the 294 remaining samples, a total of 168 somatic mutations were found. In nearly all instances (74/75–99%), the EGFR SiRe results were confirmed by Idylla. In general, SiRe analytical parameters were excellent. However, histological and cytological specimens differed in relation to average reads for sample, mean number of mapped reads, median read length and average reads for amplicon. Treatment outcome evaluation in 11 patients showed a partial response in 82 % (9/11) patients with a median progression-free survival of 340 days. Conclusions: The small gene panel SiRe is a clinically relevant tool useful to widespread the adoption of NGS in predictive molecular pathology laboratories.

15 March 2019 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
Sinchita Roy-ChowdhuriSinchita Roy-Chowdhuri
Sinchita Roy-Chowdhuri
Pasquale PisapiaPasquale Pisapia
Pasquale Pisapia
MSManuel Salto-Tellez
Manuel Salto-Tellez
SSSpasenija Savic
Spasenija Savic
MNMariantonia Nacchio
Mariantonia Nacchio
Fernando SchmittFernando Schmitt
Fernando Schmitt